دورية أكاديمية
Overview of Molecular Detection Technologies for MET in Lung Cancer.
| العنوان: | Overview of Molecular Detection Technologies for MET in Lung Cancer. |
|---|---|
| المؤلفون: | Heydt C; Faculty of Medicine, Institute of Pathology, University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany., Ihle MA; Faculty of Medicine, Institute of Pathology, University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany., Merkelbach-Bruse S; Faculty of Medicine, Institute of Pathology, University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. |
| المصدر: | Cancers [Cancers (Basel)] 2023 May 26; Vol. 15 (11). Date of Electronic Publication: 2023 May 26. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مستخلص: | MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET proto-oncogene, including MET overexpression, the activation of MET mutations, MET mutations that lead to MET exon 14 skipping, MET gene amplifications, and MET fusions, are known to be primary and secondary oncogenic drivers in cancer; these aberrations have evolved as predictive biomarkers in clinical diagnostics. Thus, the detection of all known MET aberrations in daily clinical care is essential. In this review, current molecular technologies for the detection of the different MET aberrations are highlighted, including the benefits and drawbacks. In the future, another focus will be on the standardization of detection technologies for the delivery of reliable, quick, and affordable tests in clinical molecular diagnostics. |
| References: | Brief Bioinform. 2018 May 1;19(3):450-460. (PMID: 28013235) Oncologist. 2021 Dec;26(12):e2297-e2301. (PMID: 34347347) Clin Cancer Res. 2016 Jul 15;22(14):3683-94. (PMID: 27001313) J Clin Oncol. 2016 Mar 1;34(7):721-30. (PMID: 26729443) Lancet Oncol. 2014 Aug;15(9):1007-18. (PMID: 24965569) J Thorac Oncol. 2017 Oct;12(10):1582-1587. (PMID: 28779874) Nat Med. 2014 Dec;20(12):1479-84. (PMID: 25384085) J Thorac Oncol. 2021 Jun;16(6):1017-1029. (PMID: 33676017) Cancer Discov. 2015 Aug;5(8):850-9. (PMID: 25971938) J Thorac Oncol. 2012 Feb;7(2):459-67. (PMID: 22237263) Cancers (Basel). 2022 Apr 26;14(9):. (PMID: 35565287) Ann Transl Med. 2015 Apr;3(6):83. (PMID: 25992382) Clin Cancer Res. 2013 Jan 1;19(1):215-24. (PMID: 23136195) Nat Genet. 1997 May;16(1):68-73. (PMID: 9140397) Mol Cancer Ther. 2017 Apr;16(4):555-565. (PMID: 28373408) Lung Cancer (Auckl). 2021 May 20;12:35-50. (PMID: 34295201) J Thorac Oncol. 2019 Apr;14(4):737-741. (PMID: 30639620) Clin Cancer Res. 2018 Mar 15;24(6):1337-1343. (PMID: 29284707) Cell. 1986 Jun 20;45(6):895-904. (PMID: 2423252) Oncologist. 2016 Jun;21(6):684-91. (PMID: 27151654) J Thorac Oncol. 2016 Aug;11(8):1242-1245. (PMID: 27343442) JTO Clin Res Rep. 2022 Jul 22;3(9):100381. (PMID: 36082279) Diagn Pathol. 2015 Jul 28;10:130. (PMID: 26215852) J Mol Diagn. 2022 Sep;24(9):1021-1030. (PMID: 35718095) Cancers (Basel). 2014 Oct 13;6(4):2100-15. (PMID: 25314153) Expert Opin Ther Targets. 2012 Jun;16(6):553-72. (PMID: 22530990) Br J Cancer. 2012 Jul 10;107(2):325-33. (PMID: 22644302) J Clin Oncol. 2017 Feb;35(4):412-420. (PMID: 27937096) Cancers (Basel). 2014 Sep 29;6(4):1890-904. (PMID: 25268161) Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S7-S19. (PMID: 22128289) Cancer Discov. 2020 Jul;10(7):922-934. (PMID: 32532746) Cancer. 2017 May 15;123(6):1061-1070. (PMID: 27926778) Lancet Oncol. 2016 Dec;17(12):1661-1671. (PMID: 27825638) Expert Opin Ther Targets. 2021 Apr;25(4):249-268. (PMID: 33945380) Methods Mol Biol. 2021;2279:145-155. (PMID: 33683691) Clin Cancer Res. 2009 Apr 1;15(7):2207-14. (PMID: 19318488) Clin Cancer Res. 2009 Sep 15;15(18):5714-23. (PMID: 19723643) N Engl J Med. 2020 Sep 3;383(10):931-943. (PMID: 32469185) Oncogene. 2018 Jun;37(24):3200-3215. (PMID: 29551767) N Engl J Med. 2020 Sep 3;383(10):944-957. (PMID: 32877583) Clin Cancer Res. 2014 Jul 1;20(13):3411-21. (PMID: 24658158) Cancers (Basel). 2022 Oct 01;14(19):. (PMID: 36230737) Oncogene. 1999 Jul 22;18(29):4275-81. (PMID: 10435641) J Gastrointest Oncol. 2015 Dec;6(6):618-27. (PMID: 26697193) J Mol Diagn. 2022 Aug;24(8):841-843. (PMID: 35550186) Clin Cancer Res. 2015 Aug 15;21(16):3631-9. (PMID: 25567908) Exp Hematol Oncol. 2021 Nov 10;10(1):52. (PMID: 34758872) J Thorac Oncol. 2010 Mar;5(3):305-13. (PMID: 20107422) Nat Rev Clin Oncol. 2020 Sep;17(9):569-587. (PMID: 32514147) J Thorac Oncol. 2021 May;16(5):850-859. (PMID: 33545388) Clin Cancer Res. 2016 Jun 15;22(12):3048-56. (PMID: 26847053) Ann Oncol. 2018 Dec 1;29(12):2392-2393. (PMID: 30339198) Genes Chromosomes Cancer. 2008 Dec;47(12):1025-37. (PMID: 18709663) J Thorac Oncol. 2019 Sep;14(9):1666-1671. (PMID: 31228623) Cancers (Basel). 2021 Oct 07;13(19):. (PMID: 34638507) Eur Urol. 2018 Jan;73(1):71-78. (PMID: 28592388) Clin Cancer Res. 2014 Dec 15;20(24):6336-45. (PMID: 25326232) Nat Med. 2016 Nov;22(11):1314-1320. (PMID: 27748748) Cancer Cytopathol. 2020 Sep;128(9):611-621. (PMID: 32885916) PLoS One. 2014 Aug 08;9(8):e104566. (PMID: 25105902) Bioinformatics. 2012 Jan 1;28(1):40-7. (PMID: 22039209) Oncotarget. 2016 Mar 15;7(11):13236-47. (PMID: 26910888) J Mol Diagn. 2017 Jan;19(1):4-23. (PMID: 27993330) Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11445-50. (PMID: 9326629) Oncotarget. 2021 Oct 26;12(22):2273-2282. (PMID: 34733418) Mol Cell. 2001 Nov;8(5):995-1004. (PMID: 11741535) Cancer Discov. 2015 Aug;5(8):842-9. (PMID: 25971939) Transl Lung Cancer Res. 2020 Jun;9(3):603-616. (PMID: 32676323) J Thorac Oncol. 2017 Jan;12(1):141-144. (PMID: 27664533) Cold Spring Harb Perspect Biol. 2013 Jul 01;5(7):. (PMID: 23818496) Clin Cancer Res. 2015 Feb 15;21(4):907-15. (PMID: 25492085) Comput Struct Biotechnol J. 2019 Sep 11;17:1339-1347. (PMID: 31762957) Neoplasia. 2018 Aug;20(8):838-847. (PMID: 30015159) J Thorac Oncol. 2019 Nov;14(11):2003-2008. (PMID: 31382039) Clin Cancer Res. 2019 Aug 1;25(15):4712-4722. (PMID: 31028088) J Clin Oncol. 2009 Apr 1;27(10):1667-74. (PMID: 19255323) J Thorac Oncol. 2009 Jan;4(1):5-11. (PMID: 19096300) BMC Med Genomics. 2021 Feb 27;14(1):62. (PMID: 33639937) Genes Chromosomes Cancer. 2016 Jan;55(1):30-44. (PMID: 26394895) J Mol Diagn. 2015 May;17(3):251-64. (PMID: 25801821) |
| فهرسة مساهمة: | Keywords: MET; MET exon 14 skipping mutation; MET fusion; MET gene amplification; NSCLC |
| تواريخ الأحداث: | Date Created: 20230610 Latest Revision: 20230612 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10251963 |
| DOI: | 10.3390/cancers15112932 |
| PMID: | 37296895 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2072-6694 |
|---|---|
| DOI: | 10.3390/cancers15112932 |